Fulgent Genetics, Inc. (FLGT)

As a hedge fund portfolio manager evaluating FLGT, I find the asset-backed safety net compelling. With cash ending at $551.5 million and shares trading below tangible book value (estimated net assets at $24.09–$29/share), management's opportunistic insider buying and share repurchases at $15.42 signal strong intrinsic conviction. However, until the billing-system issues resolve and stabilize collections, the path to profitability remains obscured by heavy GAAP losses.

On our options desk, implied volatility spiked drastically following the Q2 earnings miss and management's downward revision of full-year revenue expectations. Given the severe negative price reaction post-release—shedding double digits across the first few sessions—we are looking at asymmetric risk setups, potentially utilizing out-of-the-money put spreads to hedge further downside risks as customer concentration threats materialize.

From our risk management desk, the post-earnings reaction to Q2 2026 results was brutal, with double-digit drops following a $29.5 million GAAP loss and an adjusted EBITDA loss of $17.1 million. The guidance reduction to $330M–$340M reflects compounding headwinds from slower new-business growth and a key customer bringing testing in-house. We are staying on the sidelines until top-line stabilization is proven.

Looking at the operational workflow across acquisitions, the integration of Bako Diagnostics and StrataDX provided an immediate boost, pushing anatomic pathology revenue up 50% sequentially. However, the internal billing-system transition caused severe execution friction that directly degraded collections and squeezed gross margins to 31.3%. Fixing these backend administrative bottlenecks is critical for operational turnaround.

Analyzing FLGT as a bio-analyst, the core diagnostics sector is facing mixed secular performance. While Precision Diagnostics revenue declined 13% year over year to $41.5 million, BioPharma Services showed modest stabilization. Meanwhile, pipeline developments like the clinical progression of FID-007 and FID-022, alongside AI pathology tools and Epic's Aura platform integration, offer longer-term technological upside that current market pessimism obscures.